<DOC>
	<DOCNO>NCT02106910</DOCNO>
	<brief_summary>Subjects present UNC Hospitals routine endoscopic surveillance examination current Barrett 's Esophagus ( BE ) successful radiofrequency ablation ( RFA ) dysplastic Barrett 's Esophagus ( BE ) offer enrollment study . After informed consent , day endoscopic procedure , subject undergo administration Cytosponge assay . The patient undergo routine endoscopic surveillance , use standard Seattle biopsy surveillance protocol . The Cytosponge place fixative ship Fitzgerald laboratory University Cambridge processing accord establish protocol . Tissue biopsies undergo standard processing H &amp; E staining , assessment expert gastrointestinal pathologist UNC . The primary outcome variable sensitivity specificity novel assay , compare gold standard presence recurrent BE detect upper endoscopy biopsy . Secondary outcome include acceptability nonendoscopic assay patient ( assessed standardize tool , Impact Events Scale , well visual analogue scale ) , likelihood assay positivity function amount residual disease ( measure Prague criterion ) .</brief_summary>
	<brief_title>Non-Endoscopic Surveillance Barrett 's Esophagus Following Ablative Therapy</brief_title>
	<detailed_description>Esophageal Adenocarcinoma Lethal Cancer Rapidly Increasing Incidence . Barrett 's Esophagus ( BE ) Strongest Risk Factor Esophageal Adenocarcinoma . Endoscopic Ablation Induces Reversion Barrett 's Esophagus , Decreases Progression Disease . Unfortunately , data demonstrate risk recurrence BE follow successful eradication . Recent data publish candidate colleague Ablation Intestinal Metaplasia Containing Dysplasia ( AIM Dysplasia ) study demonstrate approximately 25 % subject experience successful eradication dysplastic BE develop recurrent BE . Therefore , follow successful endoscopic ablation , patient receive ongoing endoscopic surveillance . More recently , simple , non-endoscopic device , term Cytosponge , develop endoscopic screen subject risk BE . Cytosponge demonstrate sensitivity 90 % specificity 94 % detection BE . We expect investigation lead less costly , highly accurate , less invasive preferred screening paradigm large number subject undergone endoscopic ablative therapy . The Cytosponge simple , non-endoscopic device develop endoscopic screen subject risk Barrett 's esophagus ( BE ) investigator University Cambridge U.K . The Cytosponge ingestible capsule enclose compressed spherical mesh sponge 3 cm diameter , center attach string . The capsule string swallow water . The string hold mouth without tension mean cardboard tab attach string , esophageal peristalsis gravity move capsule stomach . After 5 minute ( capsule dissolve sponge liberate ) , sponge withdrawn gentle traction string , collect cell line esophagus . The sponge place fixative , cell pelleted , process paraffin block . The pellet immunostained trefoil factor 3 , interpret simply either positive negative presence staining .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<criteria>1 . Male female subject , age 1880 year , 2 . Meets follow : 2.1 . Previous diagnosis Barrett 's Esophagus ( BE ) dysplastic low grade dysplasia ( LGD ) high grade dysplasia ( HGD ) , evidence classical endoscopic appearance salmoncolored mucosa tubular esophagus , well endoscopic biopsy involve area demonstrate columnar metaplasia goblet cell . The diagnosis dysplasia must confirm second expert pathologist . Previous endoscopic mucosal resection ( EMR ) focal nodular high grade dysplasia ( HGD ) superficial intramucosal cancer ( IMC ) allowable , long EMR specimen show complete resection IMC clear margin , biopsy follow ablation confirm excision lesion , AND 2.1.1 . A history complete eradication dysplasia intestinal metaplasia radiofrequency ablation . Complete eradication define normal endoscopic appearance tubular esophagus , histologic confirmation biopsy 4 quadrant every cm throughout length previous BE ( postRFA cohort ) .OR 2.2 . Current diagnosis BE , present routine care endoscopy ( BE cohort ) . 3 . Good general health , severely debilitate disease , active malignancy , condition would interfere study participation . 1 . Current use blood thinner coumadin , warfarin , clopidogrel , heparin and/or low molecular weight heparin ( require discontinuation medication 7 day prior 7 day esophagogastroduodenoscopy [ EGD ] Cytosponge administration , aspirin use OK ) . 2 . Known bleed disorder 3 . For postRFA cohort , prior ablative therapy esophagus radiofrequency ablation ( RFA ) , include photodynamic therapy ( PDT ) , one session spray cryotherapy , ablation therapy exclusionary . However , prior endoscopic mucosal resection ( EMR ) acceptable two prior treatment thermal/coagulation therapy ( RFA ) focal residual disease follow otherwise successful RFA therapy acceptable . The BE cohort must treatment naive history ablation , prior EMR acceptable . 4 . History esophageal stricture preclude passage endoscope sponge , 5 . Pregnancy , planned pregnancy course study , 6 . Any history esophageal varix , liver impairment moderate bad severity ( Child 's Pugh class B &amp; C ) evidence varix note past endoscopy , 7 . Any history esophageal surgery , except uncomplicated fundoplication , , 8 . History coagulopathy , INR &gt; 1.3 and/or platelet count &lt; 75,000 . 9 . Planned ablation therapy within 3 day Cytosponge administration ( endoscopic mucosal resection submucosal dissection OK ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Barrett 's Esophagus</keyword>
	<keyword>Radiofrequency Ablation</keyword>
</DOC>